These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 31487030)

  • 1. The impact of EGFR-TKI use on clinical outcomes of lung adenocarcinoma patients with brain metastases after Gamma Knife radiosurgery: a propensity score-matched analysis based on extended JLGK0901 dataset (JLGK0901-EGFR-TKI).
    Yomo S; Serizawa T; Yamamoto M; Higuchi Y; Sato Y; Shuto T; Akabane A; Jokura H; Kawagishi J; Aoyama H
    J Neurooncol; 2019 Oct; 145(1):151-157. PubMed ID: 31487030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impacts of EGFR-mutation status and EGFR-TKI on the efficacy of stereotactic radiosurgery for brain metastases from non-small cell lung adenocarcinoma: A retrospective analysis of 133 consecutive patients.
    Yomo S; Oda K
    Lung Cancer; 2018 May; 119():120-126. PubMed ID: 29656746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiinstitutional prospective observational study of stereotactic radiosurgery for patients with multiple brain metastases from non-small cell lung cancer (JLGK0901 study-NSCLC).
    Shuto T; Akabane A; Yamamoto M; Serizawa T; Higuchi Y; Sato Y; Kawagishi J; Yamanaka K; Jokura H; Yomo S; Nagano O; Aoyama H
    J Neurosurg; 2018 Dec; 129(Suppl1):86-94. PubMed ID: 30544291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
    Magnuson WJ; Lester-Coll NH; Wu AJ; Yang TJ; Lockney NA; Gerber NK; Beal K; Amini A; Patil T; Kavanagh BD; Camidge DR; Braunstein SE; Boreta LC; Balasubramanian SK; Ahluwalia MS; Rana NG; Attia A; Gettinger SN; Contessa JN; Yu JB; Chiang VL
    J Clin Oncol; 2017 Apr; 35(10):1070-1077. PubMed ID: 28113019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From
    Pike LRG; Miao E; Boe LA; Patil T; Imber BS; Myall NJ; Pollom EL; Hui C; Qu V; Langston J; Chiang V; Grant M; Goldberg SB; Palmer JD; Prasad RN; Wang TJC; Lee A; Shu CA; Chen LN; Thomas NJ; Braunstein SE; Kavanagh BD; Camidge DR; Rusthoven CG
    J Clin Oncol; 2024 Oct; 42(30):3606-3617. PubMed ID: 39047224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases.
    Magnuson WJ; Yeung JT; Guillod PD; Gettinger SN; Yu JB; Chiang VL
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):673-9. PubMed ID: 27034176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis].
    Chen L; Fu M; Zhou J; Yao Y; Zhou J
    Zhongguo Fei Ai Za Zhi; 2019 May; 22(5):312-318. PubMed ID: 31109441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer.
    Cai L; Zhu JF; Zhang XW; Lin SX; Su XD; Lin P; Chen K; Zhang LJ
    J Neurooncol; 2014 Nov; 120(2):423-30. PubMed ID: 25098700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival but not brain metastasis response relates to lung cancer mutation status after radiosurgery.
    Shin SM; Cooper BT; Chachoua A; Butler J; Donahue B; Silverman JS; Kondziolka D
    J Neurooncol; 2016 Feb; 126(3):483-91. PubMed ID: 26520640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Kashima J; Okuma Y; Miwa M; Hosomi Y
    Med Oncol; 2016 Nov; 33(11):129. PubMed ID: 27757781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real world utilization of EGFR TKIs and prognostic factors for survival in NSCLC during 2010-2016 in Sweden: A nationwide observational study.
    Bergqvist M; Christensen HN; Wiklund F; Bergström S
    Int J Cancer; 2020 May; 146(9):2510-2517. PubMed ID: 31350754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic effects of immune checkpoint inhibitors in combination with stereotactic radiosurgery for patients with lung cancer and brain metastases: a propensity score-matched analysis.
    Yomo S; Oda K; Oguchi K
    J Neurosurg; 2023 Dec; 139(6):1628-1637. PubMed ID: 37243558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma.
    Chen Y; Yang J; Li X; Hao D; Wu X; Yang Y; He C; Wang W; Wang J
    Cancer Sci; 2016 Dec; 107(12):1800-1805. PubMed ID: 27627582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value and significance of brain radiation therapy during first-line EGFR-TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique.
    Gu Y; Xu Y; Zhuang H; Jiang W; Zhang H; Li X; Liu Y; Ma L; Zhao D; Cheng Y; Yu Y; Liu P; Qin J; Chen X; Gao J; Wang M; Liang L; Cao B
    Thorac Cancer; 2021 Dec; 12(23):3157-3168. PubMed ID: 34651449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved survival and intracranial tumor control of EGFR-mutated NSCLC patients with newly developed brain metastases following stereotactic radiosurgery and EGFR-TKI: a large retrospective cohort study and meta-analyses.
    Kuan AS; Chiang CL; Wu HM; Yang HC; Chen CJ; Lin CJ; Guo WY; Pan DH; Chung WY; Lee CC
    J Neurooncol; 2023 Sep; 164(3):729-739. PubMed ID: 37721662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical research on stereotactic radiosurgery combined with epithermal growth factor tyrosine kinase inhibitors in the treatment of brain metastasis of non-small cell lung cancer.
    Jia F; Cheng X; Zeng H; Miao J; Hou M
    J BUON; 2019; 24(2):578-584. PubMed ID: 31128009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases.
    Ke SB; Qiu H; Chen JM; Shi W; Chen YS
    Curr Med Sci; 2018 Dec; 38(6):1062-1068. PubMed ID: 30536070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery.
    Yang WC; Xiao F; Shih JY; Ho CC; Chen YF; Tseng HM; Chen KY; Liao WY; Yu CJ; Yang JC; Kuo SH; Cheng JC; Yang PC; Hsu FM
    Radiother Oncol; 2018 Feb; 126(2):368-374. PubMed ID: 29111173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases.
    Miyawaki E; Kenmotsu H; Mori K; Harada H; Mitsuya K; Mamesaya N; Kawamura T; Kobayashi H; Nakashima K; Omori S; Wakuda K; Ono A; Naito T; Murakami H; Endo M; Nakasu Y; Gon Y; Takahashi T
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):604-613. PubMed ID: 30851347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of first-line radiosurgery for small-cell and non-small cell lung cancer brain metastases (CROSS-FIRE).
    Rusthoven CG; Staley AW; Gao D; Yomo S; Bernhardt D; Wandrey N; El Shafie R; Kraemer A; Padilla O; Chiang V; Faramand AM; Palmer JD; Zacharia BE; Wegner RE; Hattangadi-Gluth JA; Levy A; Bernstein K; Mathieu D; Cagney DN; Chan MD; Grills IS; Braunstein S; Lee CC; Sheehan JP; Kluwe C; Patel S; Halasz LM; Andratschke N; Deibert CP; Verma V; Trifiletti DM; Cifarelli CP; Debus J; Combs SE; Sato Y; Higuchi Y; Aoyagi K; Brown PD; Alami V; Niranjan A; Lunsford LD; Kondziolka D; Camidge DR; Kavanagh BD; Robin TP; Serizawa T; Yamamoto M
    J Natl Cancer Inst; 2023 Aug; 115(8):926-936. PubMed ID: 37142267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.